Tyme Technologies Begins Phase 1b/2 Clinical Trial for the Treatment of Prostate Cancer
NEW YORK, June 13, 2016 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (OTCQB:TYMI) (“Tyme”), a clinical-stage pharmaceutical company focused on discovering and developing highly targeted cancer therapeutics for a broad range of oncology indications, …